Experimental Biology 2008
          (AAA, AAI, APS, ASBMB, ASIP, ASN, ASPET)

    Saturday April 5-Wednesday April 9, 2008
San Diego, CA

       Abstract Deadline:  November 7, 2007

ASPET Centennial Meeting

ASPET Preliminary Program
 

 ASPET Preliminary Program 

Symposia
Centennial Symposia

Sunday, April 6
  9:00 - 11:30 am

Drug Discovery Paradigms:  Past, Present & Future (Division for Drug Discovery, Development & Regulatory Affairs)
Chair:  Robert R. Ruffolo

One hundred years of drug discovery
    R. Alan North, University of Manchester
Evolution of pharmacology in drug discovery - The future is bright
    Graeme Milligan, University of Glasgow
Using mouse genetics to guide drug discovery
    Brian Zambrowicz, Lexicon Pharmaceuticals
CNS drug discovery: Back to the future.
    Sam J. Enna, University of Kansas Medical Center
Drug discovery of the future.
     Robert R. Ruffolo, Wyeth Research

The G-Whizards of GPCR/G-Protein Signaling (Division for Molecular Pharmacology, jointly sponsored by ASBMB)
Chair:  Lee E. Limbird
Stream video or download to your iPOD

How the seed was sown: The interdependent evolution of the GPCR/G protein signaling field
     Lee E. Limbird, Meharry Medical College
Seven transmembrane receptors
     Robert J. Lefkowitz, Duke University Medical Center
Where are we?
     Alfred G. Gilman, University of Texas Southwestern Medical School
Receptor-catalyzed activation of heterotrimeric G proteins
     Heidi E. Hamm, Vanderbilt University Medical Center

Julius Axelrod Symposium
Celebrating a Pioneer Pharmacologist and His Legacy:  Creating New Drugs by Revealing Mechanisms of Drug Action on Fundamental Biological Processes
Chair:  Lee E. Eiden
Stream video or download to your iPOD

A brief history of ASPET’s Julius Axelrod Award and introduction of Randy Blakely, the 2008 Julius Axelrod Awardee.
    David R. Sibley, Chair, ASPET Julius Axelrod Award Committee; NINDS, NIH
Julie Axelrod: A legacy of fundamental research for drug discovery.
   Lee E. Eiden, NIMH, NIH
Methylation pharmacogenomics: Neurotransmitters to drug response.
   Richard M. Weinshilboum, Mayo Clinic College of Medicine
Neurotransmitter transporters: New views of form and function
   Susan G. Amara, University of Pittsburgh School of Medicine
Biochemical and behavioral actions of monoamines in genetic animal models
   Marc G. Caron, Duke University Medical Center

Cannabinoid CB1 Receptor Interdependence with Other Receptor Systems as a Target for Medication Development
(Sponsored by the Divisions for Behavioral Pharmacology, Neuropharmacology, Molecular Pharmacology, Systems & Integrative Pharmacology)
Chair:  Steven R. Goldberg

Introduction: Cannabinoid CB1 receptor interdependence with other receptor systems as a target for medication development
    Steven R.Goldberg, NIDA, NIH
Cannabinoid CB1 receptors form functional heteromers with dopamine, adenosine and opioid receptors 
    Sergi Ferre, NIDA, NIH
Drug-discrimination and in-vivo microdialysis procedures for studying nicotinic, dopaminergic and opioid receptor interactions with cannabinoid CB1 receptors in rats.
    Marcello Solinas, University of Poitiers, France
Drug self-administration and conditioned place preference procedures for studying interactions between cannabinoid CB1 receptors and other receptor systems in rodents
   Walter Fratta, University of Cagliari, Italy
Intravenous drug self-administration procedures in nonhuman primates for studying interactions between cannabinoid CB1 receptors and other receptor systems
   Zuzana Justinova, University of Maryland School of Medical
Cannabinoid CB1 receptor interdependence with other receptor systems as a target for medication development: Future directions and potential payoff for human health in the next 10 years
   TBD

Pharmacology Education for the Next 100 Years:  Preparing the Next Generation of Pharmacologists
Sponsored by the Division for Pharmacology Education
Chairs:  Lynn M. Crespo and Joey V. Barnett

Pharmacologists in Pharma.
     D. Euan MacIntyre, Merck Research Laboratories
Pharmacologists in government and regulation.

     Aisar H. Atrakchi, FDA
Pharmacologists in academia.
     Jordan E. Warnick, University of Maryland School of Medicine
The pharmacology curriculum - past vs. present
     Lynn M. Crespo, University of Central Florida College of Medicine

Sunday, April 6
  2:30 - 5:00 pm

Pharmacotherapeutics for Drug Abuse - The Cocaine Challenge (Division for Behavioral Pharmacology)
Chair:  Alice M. Young

Pharmacological modification of drug taking: Origins and evolution.
     William Woolverton, University of Mississippi Medical Center
Cocaine: Consequences of rapid elimination.
     James H. Woods, University of Michigan Medical School
Benztropine-related dopamine uptake blockers that prevent cocaine effects
    Jonathan Katz, NIDA, NIH
Employment-based reinforcement in the treatment of cocaine addiction.
     Kenneth Silverman, Johns Hopkins University
Where will it go in ten years?
     Maxine L. Stitzer, Johns Hopkins Bayview Medical Center

Chance Favors the Prepared Mind: A Nobel Perspective (

The role of serendipity and luck in the discovery of the NO and cyclic GMP signaling pathway and their exciting future in drug development
     Ferid Murad, University of Texas, Houston
When you come to a fork in the road, take it
     Alfred G. Gilman, University of Texas Southwestern Medical Center
The road to Stockholm - A Nobel mission
     Louis J. Ignarro, UCLA School of Medicine

Regulation for Ion Channels in Cardiovascular Disease
(Sponsored by the Divisions for Cardiovascular Pharmacology and Molecular Pharmacology)
Chairs:  Swapnil Sonkusare and Nancy J. Rusch

Distinct regulation of L-type Ca(2+) channels localized to caveolae in heart
   Timothy J. Kamp, University of Wisconsin
The role of potassium channels in neurovascular coupling
   Mark T. Nelson, University of Vermont
Auto-inhibitory control of L-type Ca(2+) channels in heart
   William A. Catterall, University of Washington School of Medicine
Vascular ion channel remodeling in hypertension
   Swapnil Sonkusare, University of Arkansas for Medical Sciences
Regulation of K(+) channels in nitrate tolerant arteries
   Stephen T. O'Rourke, North Dakota State University College of Pharmacy

G12/13 Signaling of Cell Surface Receptors:  Molecular Insights & Disease Context
(Sponsored by the Divisions for Molecular Pharmacology, Cardiovascular Pharmacology, and the  American Society of  Biochemistry and Molecular Biology)
Chair:  Sandra Siehler

Physiological relevance of Galpha₁₂ and Galpha₁₃ in various tissues
   Stefan Offermanns, University of Heidelberg, Germany
Role of G_12/13 signaling in cancer invasion and metastasis
   Patrick J. Casey, Duke University Medical Center
Regulation of phospholipase C-epsilon by G_12/13 and RhoA
   T. Kendall Harden, University of North Carolina School of Medicine
Novel localizations and functions of G_12/13-regulated RGS-RhoGEFs
   Philip Wedegaertner, Thomas Jefferson University
Mechanistic insights and therapeutic impact of G_12/13–related signaling of G protein-coupled receptors
   Sandra Siehler, Novartis Pharma AG, Basel, Switzerland

Monday, April 7
  9:00 - 11:30 am

P450s: Structure, Function, In Silico Predictions

Drug metabolism and cytochrome P450
   Anthony Y.H. Lu, Rutgers University
Mechanisms of P450-dependent drug oxidation
   Paul R. Ortiz de Montellano, UCSF
Protein and substrate dynamics of cytochromes P450
   William Atkins, University of Washington
Crystal structures of P450 active sites
   Eric F. Johnson, Scripps Research Institute
In silico predictions of P450 catalysis
   Lovisa Afzelius, AstraZeneca R&D

The Obesity Epidemic – Pharmacological Challenges (Division for Systems & Integrative Pharmacology)
Chair:  Ismail Laher

The current molecular model of body weight regulation
   Matthias H. Tschoep, University of Cincinnati College of Medicine
Pharmacological therapy of obesity
   D. Scott Weigle, University of Washington 
Physiological regulators of appetite as a basis for pharmacotherapy of obesity
   Stephen R. Bloom, Hammersmith Hosp., Imperial College London, UK
The endocannabinoid system as a new regulator of energy balance
   Xavier Pi-Sunyer, St. Luke's/Roosevelt Hospital
Fatty acid metabolism and energy regulation: New pharmacological strategies for obesity therapy
   Gabriele Ronnett, Johns Hopkins Bayview Medical Center
                         

Ray Fuller Symposium
     Preceded by the Ray Fuller Lecture from 8:00  - 8:50 am
Antidepressants for the New Millennium:  Circumventing the Monoamine Synapse
Chair:  Phil Skolnick
Stream video or download to your iPOD

The role of the NMDA receptor signaling cascade in antidepressant activity.
    Ian A. Paul, University of Mississippi Medical Center

Neurotrophic and neurogenic actions of antidepressants. 
    Ron S. Duman, Yale University School of Medicine

AMPA receptor potentiation: A core antidepressant pathway?
    Jeffrey M. Witkin, Eli Lilly and Co.

Potentiation of synaptic AMPA/NMDA mediated throughput in the development of novel therapeutics for mood disorders.
    Carlos Zarate, NIMH, NIH

The Emerging Science of Drug Safety
(Sponsored by the Divisions for Clinical Pharmacology, Translational Medicine & Pharmacogenomics, Drug Discovery, Development & Regulatory Affairs, Toxicology, Behavioral Pharmacology, Cardiovascular Pharmacology, Drug Metabolism)
Chairs:  Darrell R. Abernethy and Judith K. Jones

Introduction. Darrell R. Abernethy, U.S. Pharmacopeia
Approaches to enhance drug safety in the ambulatory outpatient setting
   Michael Murray, University of North Carolina School of Pharmacy
Identification and evaluation of drug induced disease
   Judith K. Jones, The Degge Group, Ltd., Arlington, VA
European experience with active surveillance methods to identify drug safety problems
   Sir Alasdair M. Breckenridge, Medicines and Healthcare Products Regulatory Agency, London, U.K.
Development of informatics to support post-marketing surveillance in the United States
   Kenneth D. Mandl, Harvard-MIT

Monday, April 7
  2:30 - 5:00 pm

Epoxide hydrolases, from xenobiotic metabolism to pharmaceutical target
   Michael Arand, University of Zurich, Switzerland
Stabilization of epoxyeicosanoids by inhibitors of the soluble epoxide hydrolase as treatments for hypertension, vascular inflammation and end organ damage
   John D. Imig, Medical College of Wisconsin
Genetic polymorphisms of the soluble epoxide hydrolase are associated with risk of stroke and vascular disease
   Darryl C. Zeldin, NIEHS, NIH
Biochemistry, structure and the design of inhibitors for the soluble epoxide hydrolase
   Bruce D. Hammock, University of California - Davis
Translation of soluble epoxide hydrolase inhibitors to the clinic
   Heather Webb, Arête Therapeutics
The impact of research on epoxide hydrolases and epoxyeiconsanoids on human health
   William B. Campbell, Medical College of Wisconsin

New Concepts in an Old System - Renin-Angiotensin System Blockade as Therapy for General Cardiovascular Disease (Division for Cardiovascular Pharmacology)
Chair:  Mariana Morris and Carlos M. Ferrario

Renin angiotensin system - A historical perspective.
    Ronald D. Smith, Merck, Inc.

Renin inhibition and renin receptors.
    Genevieve Nguyen, INSERM U833, Collège de France, Paris

ACE2 as a new target in the RAS.
    Mark C. Chappell, Wake Forest University School of Medicine

RAS and the cardiovascular pathologies associated with diabetes.
     Khalid M. Elased, Wright State University

RAS and inflammatiion in cardiovascular disease.
    Lisa A. Cassis, University of Kentucky College of Pharmacy

Contribution of tissue RAS inhibition to therapeutic effectiveness.
    Michael Bader, Max-Delbrück-Centrum, Berlin

Neuroplasticity in Addiction:  Picking up the Pieces
(Sponsored by the Divisions for Neuropharmacology, Behavioral Pharmacology, Systems & Integrative Pharmacology)
Chair:  Peter W. Kalivas

Role of animal models in understanding cellular neuroplasticity
   George F. Koob, Scripps Research Institute
Role of nucleus accumbens CREB in addiction and depression: Implications for co-morbidity
   William A. Carlezon, Harvard Medical School/McLean Hospital
Long-term changes in synaptic efficiency by drugs of abuse
   Antonello Bonci, UCSF
How molecular plasticity in corticolimbic circuitry translates into novel therapeutics
   Peter W. Kalivas, Medical University of South Carolina
Neural encoding of negative affect and its relationship to drug seeking
   Robert A. Wheeler, University of North Carolina

Tuesday, April 8
   9:00 - 11:00 am

ABC Transporters:  From Drug Resistance to Drug Response (Division for Clinical Pharmacology, Translational Medicine, & Pharmacogenomics)
Chair:  Richard B. Kim

ABC transporters: Historical perspective and importance in drug disposition
   Susan P.C. Cole, Queen's University
ABC transporters and cancer chemotherapy
   Susan E. Bates, NCI, NIH
From Mdr1 to Bcrp knockout mice: Relevance to xenobiotic toxicity
   Alfred H. Schinkel, The Netherlands Cancer Institute
Interplay between ABC transporters and cytochrome P450 enzymes
   Erin G. Schuetz, St. Jude's Children's Research Hospital
ABC transporters, where do we go from here?
   Richard B. Kim, University of Western Ontario, London Health Science Center Hospital

New Experimental Approaches to Treatment of Schizophrenia: Moving Beyond Monoamine Antagonists (Division for Neuropharmacology)
Chairs:  P. Jeffery Conn and Carol A. Tamminga

Treatments for schizophrenia: Targeting psychosis and cognition
   Carol A. Tamminga, University of Texas Southwestern Medical Center
Allosteric activators of muscarinic receptors as a novel approach for treatment of schizophrenia
   P. Jeffrey Conn, Vanderbilt University
Metabotropic glutamate receptors as novel targets for treatment of schizophrenia: Progress, issues, and challenges
   Darryle D. Schoepp, Merck Research Labs
De novo design of potent GlyT1 inhibitors: In vitro and in vivo profiles
   Craig W. Lindsley, Vanderbilt University Medical Center

Integrative Urogenital Pharmacology:  Implications to the Treatment of Bladder Disease
(Sponsored by the Divisions for Systems & Integrative, Drug Discovery, Development & Regulatory Affairs)
Chairs:  George J. Christ and Karl-Erik Andersson

K channel modulation of bladder contractility
   Mark T. Nelson, University of Vermont
Molecular mechanisms of bladder dysfunction
   George J. Christ, Wake Forest University Baptist Medical Center, WFIRM
Integrative control of bladder function: From the CNS to the urothelium
   William C. de Groat, University of Pittsburgh Medical School
Modulation of electromechanical coupling in the bladder.
   Chris Fry, University College London
Pharmacological basis and mechanisms for treatment of overactive bladder
    Karl-Erik Andersson, University of Lund, Sweden/Wake Forest University Baptist Medical Center, WFIRM

Drug Metabolism, Bioactivation & Chemical-induced Toxicities:  Lessons Learned & Contemporary Issues
(Sponsored by the Divisions for Drug Metabolism, Toxicology, Clinical Pharmacology, Translational Medicine & Pharmacogenomics, Systems & Integrative Pharmacology)
Chair: Terry J. Monks and Kenneth E. Thummel

Drug toxicites - Lessons learned
   M.W. Anders, University of Rochester
Cytochrome P450 mediated drug bioactivation and idiosyncratic toxicities
   B. Kevin Park, University of Liverpool. UK
Immune-based drug toxicities 
   Jack Uetrecht, University of Toronto
GSH-conjugate mediated neurotoxicity
   Terry J. Monks, University of Arizona
Transporters and drug-induced toxicities
   Susan P.C. Cole, Queen's University, Canada
 

Wednesday, April 9
  8:00 -  10:30 am   - NOTE EARLIER TIME!¾

Inflammation:  Early Disease Marker, Drug Response Modifier, Therapeutic Target
(Sponsored by the Divisions for Drug Discovery, Development & Regulatory Affairs, Clinical Pharmacology, Translational Medicine & Pharmacogenomics,  Molecular Pharmacology, Toxicology, Systems & Integrative Pharmacology, Drug Metabolism)
Chairs:  Donald W. Miller and Daniel S. Sitar

Omics-based discovery of inflammation markers as diagnostic tools in drug discovery and disease
   B. Alex Merrick, NIEHS, NIH
Idiosyncratic drug-induced liver injury and inflammatory stress
   Patricia E. Ganey, Michigan State University
Role of the blood-brain barrier in central nervous system inflammation
   Donald W. Miller, University of Manitoba, Canada
Emerging anti-inflammatory therapeutics: Perspectives from the laboratory
   David E. Szymkowski, Xencor, Inc.
Emerging anti-inflammatory therapeutics: Perspectives from the clinic
   Robert I. Fox, Scripps Memorial Hospital & Research Foundation

Emerging Importance of Allosteric Receptor Modulation in Drug Discovery
Sponsored by the Divisions for Neuropharmacology, Systems & Integrative Pharmacology, Drug Discovery, Development & Regulatory Affairs, Behavioral Pharmacology, Molecular Pharmacology, Clinical Pharmacology, Translational Medicine & Pharmacogenomics
Chair:  Guibao Gu

Topography in drug discovery: The challenge of allosteric modulators
   Arthur Christopoulos, Monash University, Australia
Positive allosteric modulation of GABAB receptors: A novel therapeutic strategy for anxiety and drug dependence
   John F. Cryan, University College Cork, UK
Allosteric modulation of serotonin transporters: Lessons learned from the development of escitalopram
    Connie Sanchez, Lundbeck  Research USA
Allosteric modulation of GPCRs as a novel therapeutic direction for the treatment of CNS disorders
   Colleen Niswender, Vanderbilt University Medical Center

The Promise and Challenges of Pharmacogenetics as a Diagnostic Tool
Sponsored by the Divisions for Clinical Pharmacology, Translational Medicine & Pharmacogenomics, Drug Metabolism, Systems & Integrative Pharmacology, Toxicology
Chair:  Steven Leeder

The use of pharmacogenetics to optimize cancer chemotherapeutics in children
   William E. Evans, St. Jude Children's Research Hospital
Predictive tests for asthma exacerbations and short acting response to brochodilator medication: Use of whole genome data
   Scott T. Weiss, Brigham and Women's Hospital, Harvard Medical School
Genetic variation in statin response
   Ronald Krauss, Children's Hosp. Oakland Research Institute
Pharmacogenetics as a diagnostic tool for psychotic illnesses
   Herbert Y. Meltzer, Vanderbilt University Medical Center

Mitochondria in Life & Death: From Biogenesis to Autophagy
(Sponsored by the Division for Toxicology)
Chair:  Rick G. Schnellmann

The mitochondrial proteome
    Bradford W. Gibson, Buck Institute for Age Research
Protein kinase signaling of mitochondrial function following injury
    Grazyna Nowak, University of Arkansas for Medical Sciences
Mitochondrial permeabilization in cell death and mitophagy
    John J. Lemasters, Medical University of South Carolina
Mitochondrial biogenesis following oxidant injury
    Rick G. Schnellmann, Medical University of South Carolina

A Century of Development of Concepts of Ion Channel Receptors: Past Milestones and Contemporary Development for the Next Decade
(Sponsored by the Divisions for Molecular Pharmacology, Behavioral Pharmacology, Neuropharmacology, and the  American Society of  Biochemistry and Molecular Biology)
Chair:  Palmer W. Taylor 

The era of chemical characterization of ion channel receptors: The importance of investigating  conformation and state changes.      Jean-Pierre Changeux, Institut Pasteur, Paris
The acetylcholine binding protein: A model system for nicotinic acetylcholine receptor selectivity. 
    Titia Sixma, The Netherlands Cancer Institute, Amsterdam
Roles of nicotinic receptors in nicotine addiction and neuroprotection.
    Henry A. Lester, Cal Tech
Dynamics in structure-guided drug design: Structurally defined receptors as templates for freeze-frame, click chemistry synthesis of novel ligands.
    Palmer W. Taylor, UCSD

Division Sessions

Sunday, April 6
  2:30 - 5:00 PM

Drug Metabolism Division James Gillette Best Paper Award Winners Platform Session 
Chairs:  Ken E. Thummel and Tom A. Kocarek

Monday, April 7
  2:30 - 5:00 PM

Translational Research in Behavioral Pharmacology - Division for Behavioral Pharmacology
Chairs:  Charles P. France and Alice M. Young

Translational medicine in pain research.
    James E. Barrett, Drexel University College of Medicine

Challenging the opiates: Concept, target identification and profile of the central analgesic, F 13640.
    Francis C. Colpaert, Centre de Recherche Pierre Fabre, Castres, France

Use of behavioral pharmacology in rational drug discovery for novel targets in psychiatric disorders.
    Darryle D. Schoepp, Merck and Co.

Cognitive disturbances in depression: Preclinical targets for antidepressant treatment.
    Alan Frazer, University of Texas Health Science Center at San Antonio

Ion Channel Therapy & Disease Therapy  - Division for Systems & Integrative Pharmacology
Chairs:  Robert S. Kass and Mark T. Nelson

Voltage gated Na channel disorders and excitable tissues.
    Alfred L. George, Vanderbilt University Medical Center

K channels and the long QT syndrome.
    Robert S. Kass, Columbia University Medical Center

CRAC channel regulation in health and disease.
    Richard S. Lewis, Stanford University School of Medicine

Probing the genetic and molecular basis of episodic neurological disease
    Louis J. Ptacek, University of California - San Francisco
Cellular mechanism of arrhythmogenesis in a murine model of congenital cathecholaminergic polymorphic
ventricular tachycardia (CPVT).
    Marco Mongillo, Columbia University College of Physicians and Surgeons

Tuesday, April 8
  9:00  - 11:30 AM

Signal Transduction Bioinformatics:  Integrating Pharmaoclogy with Signaling Molecule Discovery - Division for Drug Discovery, Development & Regulatory Affairs
Chair:  Lee E. Eiden

Introduction: Drug discovery, signaling molecule discovery and integrationg pharmacology into bioinformatics tools for signal transduction analysis.
    Lee E. Eiden, NIMH, NIH

Pathfinder: A static network analysis tool for pharmacological analysis of signal transduction pathways, and other transduction bioinformatics tools.
    Babru B. Samal, NIMH, NIH

Phosphoproteomics-based kinase substrate discovery in growth factor signaling.
    Michael J. Comb, Cell Signaling Technology, Inc.

Integrating pharmacology into network analysis of signal transduction.
    Ravi Iyengar, Mount Sinai School of Medicine

Pathway analysis in bioinformatics-nodal inhibition and its relevance to drug discovery.
    Gary D. Bader, University of Toronto

Defining drug targets in yeast haploinsufficiency screens: Application to human translational pharmacology.
    Michel Roberge, University of British Columbia Faculty of Medicine

Roundtable discussion 
    Nancy R. Gough, Science’s STKE

Tuesday, April 8
  2:30 - 5:00 PM

Neuropharmacology Postdoctoral Scientist Award Finalists
Chair: David R. Sibley

Ethanol potentiation of D₁ receptor signaling: The role of PKC
    David R. Sibley, NINDS/NIH
 

Postdoctoral Scientist Award Presentations:

    Cellular and molecular mechanisms regulating MT₁ and MT₂ melatonin receptor trafficking.
       Yahong Zhang, Northwestern University School of Medicine

    Comparison of dopamine transporter regulation in rat dorsal striatum versus nucleus accumbens
       Toni L. Richards, University of Colorado - Denver

    Sex differences in the corticotropin-releasing factor receptor and its regulation by stress

       Debra Bangasser, Children’s Hospital of Philadelphia

    Chronic treatment with paliperidone, like lithium and valproate, induces similar changes in expression and phosphorylation at

    the synaptoneurosomal level in rat prefrontal cortex

  Maria Corena Mcleod, Mayo Clinic, Jacksonville

    Role of NOS-NO signaling in clonidine-ethanol evoked synergistic behavioral impairment
       Tara S. Bender, East Carolina University

Role of Transporters in Prevention and Exacerbation of Toxicity - Division for Toxicology
Chair:  Mary E. Vore

Characterization of mice null for liver-specific uptake tranpsorter Oatp1b2.
    Curtis D. Klaassen, University of Kansas Medical Center

Regulation of yeast MRP Ycf1p by protein-protein interaction.
    Christian M. Paumi, John Hopkins School of Medicine

Glutathione transporters as key regulators of the biological functions of the tripeptide.
    Ned Ballatori, University of Rochester

Modulation of electrophile-mediated signaling by MRP1, GSH and GST.
    Charlie S. Morrow, Wake Forest University School of Medicine

Drug Response Predictions: Genotype vs. Phenotype - Division for Clinical Pharmacology, Translational Medicine and Pharmacogenomics Division

Chair:  Richard B. Kim

Phenotype predictions from genotype: Examples from CYP2D6.
    Andrea Gaedigk, Children’s Mercy Hospital, Kansas City, MO

CYP3A5: How important is this enzyme to drug response?
    Evan D. Kharasch, Washington University

In vivo probes of MDR1 and BCRP activity in humans.
    Ute I. Schwarz, University of Western Ontario
Abstract 4856:  Prediction of individual variation in thiopurine response phenotypes from genome-wide association studies
    Fan Li, Mayo Clinic College of Medicine 
Abstract 6187:  Expression and functional characterization of murine organic anion transporting polypeptide 1b2 (oatp1b2/ oatp4/ lst-1)
    Henriette Meyer zu Schwabedissen, University of Western Ontario

Abstract 8836: Dysregulation of intestinal CYP3A4-dependent 1,25-dihydroxyvitamin D3 catabolism: a potential mechanism for drug-induced osteomalacia
    Emily Zheng, University of Washington 

Molecular Pharmacology Division Postdoctoral Award Finalists
Chair:  T. Ken Harden

Connecting A to B - and phospholipase C
     T. Ken Harden, University of North Carolina

Suppression of IgE-mediated allergic responses by Rgs13
    Geetanjali Bansal. NIAID, NIH. (Advisor: K.M. Druey).

PAR1-mediated stable platelet aggregation requires temporal regulation of Rap1 activity by phosphatidylinositol

phosphates (PIPns)
    Michael Holinstat. Vanderbilt University Medical Center. (Advisor: H.E. Hamm).

[beta]1 adrenergic receptor ([beta]1AR)-epidermal growth factor receptor (EGFR) interaction regulates ERK cellular

activity
    Douglas G. Tilley. Duke University Medical Center. (Advisor: H.A. Rockman).

Unraveling the molecular mechanism by which the L148S mutation of GPR54 causes idiopathic hypogonadotrophic

       hypogonadism
    Jennifer L. Wacker. University of Washington. (Advisor: C. Hague).

Regulation of TGF-beta signaling by RGS3
    Douglas M. Yau. University of Chicago. (Advisor: N. Dulin).

Cardiovascular Pharmacology Division Junior Scientists Competition
Chairs:  John C. Kermode, Fadi Khasawneh and Jianzhong Shen

Graduate Student Presentations:

    O-GlcNAc signaling attenuates mitochondrial permeability transition
       Gladys A. Ngoh, University of Louisville (Advisor: Steven P. Jones)

    Inhibitory phosphorylation of TASK-1 is associated with atrial fibrillation
       Erin Harleton, Columbia University (Advisor: Steven J. Feinmark)

    Shaker K_v1 channel-MAGUK complexes are down-regulated in cerebral arteries of hypertensive rats
       Biny K. Joseph. University of Arkansas for Medical Sciences (Advisor: Nancy J. Rusch)

    Improvement of cardiac contractility by proteasome inhibition in the overload heart
       Nadia Hedhli, University of Medicine and Dentistry of New Jersey (Advisor: Christophe Depre)
 

Postdoctoral Scientist Presentations:

    Ca²⁺ pulsars: spatially restricted, IP₃R-mediated Ca²⁺ release important for endothelial function
       Jonathan Ledoux, University of Vermont (Mentor: Mark T. Nelson)

    12- and 15-hydroxyeicosatetraenoic acids may function as endothelium-derived hyperpolarizing factors in the human coronary

    microcirculation
        Brandon T. Larsen, Medical College of Wisconsin (Mentor: David D. Gutterman)

 

Graduate Student Runners-up Posters:

    A novel mechanism of angiotensin II-induced cardiac hypertrophy -- The role of soluble epoxide hydrolase
       Ding Ai, University of California at Davis (Advisor: Yi Zhu)

    Soluble epoxide inhibition differentially modulates flow induced vascular remodeling in spontaneously hypertensive stroke prone

    rats and Wistar Kyoto rats
       Alexis N. Simpkins, Medical College of Georgia (Advisor: John D. Imig)

    Accessory ₃ subunits promote the functional expression of voltage-gated calcium channels in vascular smooth muscle
    cells
       Swapnil Sonkusare, University of Arkansas for Medical Sciences (Advisor: Nancy J. Rusch)

    Compartmentation of cellular cGMP-signalling: a mechanism for spatial and temporal regulation of cGMP mediated

    effects

       Lindsay S. Wilson, Queen's University (Advisor: Donald Maurice)

 

Postdoctoral Scientist Runner-up Poster:

    Platelet growth factor regulates smooth muscle cell migration through an integrin-linked kinase-dependent pathway
       Mitra Esfandiarei, Child and Family Research Institute, University of British Columbia (Mentor: Cornelius van Breemen)

Tuesday, April 8
  4:30 - 5:30 PM

Cardiovascular Pharmacology Division Paul M. Vanhoutte Distinguished Award Lecture
Chair: David D. Ku

Lecturer:  Donald D. Heistad, University of Iowa
    Endothelial function in the time of the giants

Special Sessions

Saturday, April 5
  12:30 - 3:00 PM

Implications of Pharmacogenomics for Health Disparities
(Sponsored by the Committee on Diversity)
Chairs:  Sakina E. Eltom and Martha I. Davila-Garcia

Genetics and health disparities in cardiovascular drug therapy.
   Dan M. Roden, Vanderbilt University School of Medical
Pharmacogenomics and health disparities in cancer disease
   Howard L. McLeod, University of North Carolina School of Pharmacy
Racial differences in nicotine pharmacology: Implications for disease risk and addiction
   Neal L. Benowitz, UCSF

2008 Teaching Institute
How to Teach Graduate Students
Chair:  William B. Jeffries

Principles of adult learning.
    Katie N. Huggett, Creighton University
Designing and teaching a graduate course.
    Jason C. Bartz, Creighton University
Mentoring graduate students.
    Stephanie W. Watts, Michigan State University
Running a graduate program.
    Joey V. Barnett, Vanderbilt University
Competency based education in pharmacology graduate programs.
    William B. Jeffries, Creighton University School of Medicine

Saturday, April 5
  3:15 - 5:45 PM

Graduate Student/Postdoctoral Colloquium
Learning from the Past, Training for the Future

Current trends in pharmacology training.
    Joey V. Barnett, Vanderbilt University

What you need to be a success in regulatory affairs.
    Nancy Sevieux, Proctor and Gamble

Necessary skills to build a career at the bench in industry.
    Lisan L. Parker, Merck Research Laboratories

Tuesday, April 8
  8:00 - 10:00 AM

ASPET’s Women in Pharmacology Committee and APS’ Women in Physiology Committee Workshop
Gainfully Employed: From Launching a Job Search to Navigating Negotiations
Chairs:  Sinya Benyajati, Colleen Hegg and Jelveh Lameh

This career development symposium will address the needs of early career scientists who will soon transition into a ‘new’ professional appointment.  The workshop will provide information regarding 1) launching a job search, particularly for a dual-career couple, 2) delivering a job talk: formal seminar vs. chalk-talk, 3) the art of interviewing, and 4) negotiation tips.

Launching the “successful” job search.
    Colleen Cosgrove Hegg, Michigan State University
Delivering a dynamic job talk.
    Susan C. McKarns, NIAID, NIH
The art of interviewing: winning the job.
    Lynn Wecker, University of South Florida College of Medicine
Navigating negotiations.
   Kim E. Barrett, UCSD

Interactive exercises and mock interviews.

Tuesday, April 8
  12:00 - 2:15 PM

Poster Discussion
Epoxide Hydrolases
Chairs:  Bruce D. Hammock, John D. Imig ,  Curt J. Omiecinski, and Christophe Morisseau

Lectures 

Sunday, April 6
  1:30 - 2:20 pm

Bernard B. Brodie Award Lecture:   Hepatobiliary disposition of xenobiotics
   Curtis D. Klaassen, University of Kansas Medical Center

Monday, April 7
   8:00 - 8:50 am

Ray Fuller Lecture - Broad Spectrum Antidepressants:  Variations on a Monoamine Theme
     Phil Skolnick, Dov Pharmaceuticals, Inc.
        Followed immediately by the Ray Fuller Symposium
        Stream video or download to your iPOD

Monday, April 7
   1:30 - 2:20 pm

P. B. Dews Award Lecture:  Contributions of behavioral pharmacology to our understanding of the etiology, prevention and treatment of substance abuse
    Charles R. Schuster, Loyola University

 

Satellite Meetings

FRIDAY & SATURDAY, April 4-5

Recent Advances in Muscarinic Receptor Pharmacology and Therapeutics Colloquium

Third RGS Protein Colloquium

Behavioral Pharmacology Society Meeting
Contact Galen R. Wenger:  grwenger@uams.edu or 501-686-8040
book

Public Affairs Sessions

General Information

Call for Abstracts

Hotels

Registration